BioCentury | Aug 4, 2020
Politics, Policy & Law

China doubling size of centralized procurement program

Six months after the last round of price cuts for generics and off-patent originator drugs in China’s centralized procurement program, the Chinese government has outlined plans to nearly double the number of included drug formulations....
BC Week In Review | Aug 3, 2018
Clinical News

Additional study needed for RedHill's Crohn disease candidate

RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) said another Phase III trial is "most likely to be required" to support an NDA submission to FDA for Crohn disease candidate RHB-104. On a conference call to discuss...
BC Extra | Jul 30, 2018
Clinical News

Additional study needed for RedHill's Crohn disease candidate

RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) said another Phase III trial is "most likely to be required" to support an NDA submission to FDA for Crohn disease candidate RHB-104. On a conference call Monday to...
BC Extra | Jul 5, 2018
Preclinical News

Antibiotic combos could yield narrow-spectrum therapies

Newly identified synergistic antibiotic combinations could lead to narrow-spectrum therapies for Gram-negative infections, including multidrug resistant (MDR) strains. The research appeared in a Nature article from European Molecular Biology Laboratory (EMBL) and colleagues. The group...
BC Innovations | Jan 4, 2018
Distillery Techniques

Chemistry

TECHNOLOGY: Synthetic chemistry A photoexcitable catalyst-based method could incorporate deuterium or tritium labels into drug compounds for use in ADME and other assays for measuring drug properties. The method involves reacting a drug compound with...
BC Innovations | Dec 13, 2017
Distillery Therapeutics

Infectious disease

INDICATION: Helicobacter Cell culture and mouse studies suggest an acid-activated antimicrobial peptide could help treat Helicobacter pylori infection without affecting commensal bacteria. The peptide comprises anionic and cationic amino acid residues that adopt a random...
BC Innovations | Sep 11, 2017
Distillery Techniques

Drug delivery

TECHNOLOGY: Nanoparticles Gas-propelled nanoparticles could be used to deliver therapies to treat stomach infections. The nanoparticles consist of three layers: an outer layer of chitosan polymer for electrostatic adhesion to the gastric mucosa; a middle...
BC Week In Review | Aug 18, 2017
Clinical News

DSMB recommends continuation of RedHill's Phase III trial of RHB-104 for CD

RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) said an independent DSMB recommend for a second time continuation of the Phase III MAP US trial of RHB-104 to treat Crohn’s disease (CD) based on efficacy and safety...
BC Week In Review | Mar 30, 2017
Clinical News

RHB-104: MAP US2 extension started

RedHill began the open-label, international Phase III MAP US2 extension study to evaluate oral RHB-104 in about 100 patients who have completed 26 weeks of treatment in the double-blind, placebo-controlled, international Phase III MAP US...
BC Week In Review | Jan 25, 2017
Clinical News

RHB-104 regulatory update

FDA granted Qualified Infectious Disease Product (QIDP) and Fast Track designation to RHB-104 from RedHill to treat non-tuberculosis mycobacterial (NTM) infections. The product is a capsule formulation of the generic antibiotics clarithromycin, rifabutin and clofazimine....
Items per page:
1 - 10 of 90